Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Freiburg im Breisgau, Germany Clinical Trials

A listing of Freiburg im Breisgau, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (14) clinical trials

EDoF IOLs vs Monofocal IOL

prospective, comparative (3 arms), randomized, multicentric clinical trial

Phase

0.0 miles

Learn More »

A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment

A study comparing a treat-to-target (T2T) intense treatment approach in participants with axial spondyloarthritis (axSpA) with routine treatment (Standard of Care (SOC)) concerning a reduction in disease activity.

Phase

0.43 miles

Learn More »

Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

The purpose of the study is to determine the effect of LCZ696 vs. Enalapril on improvement of excercise capacity in patients with chronic heart failure with reduced ejection fraction

Phase

0.43 miles

Learn More »

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

This is a Phase IV, multi-center, randomized, open-label study. Eligible patients will start pasireotide subcutaneously (s.c.) for Cushing's disease and pasireotide LAR (long-acting release) for acromegaly. Patients currently treated at screening visit with pasireotide s.c. or LAR are eligible as long as they meet protocol criteria during the screening period. ...

Phase

0.43 miles

Learn More »

Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients

This is a national multicenter, double-blind, randomized placebo-controlled trial allowing for a minimum follow-up time of 24 months in conversion-free patients. Randomization will be stratified by prior use of statins. The two strata are: "no-statins": patients without treatment with a statins and no indication for treatment (according to the guidelines ...

Phase

0.43 miles

Learn More »

Effects of Pregabalin on Mechanical Hyperalgesia

This randomized controlled trial is intended to be the first in a series of trials that will assess the efficacy of drugs, which relieve neuropathic pain, on stimulus-evoked pain (here: mechanical hyperalgesia to static punctate stimuli). Most drugs in this class (e.g. Gabapentin or NMDA receptor inhibitors) have NNT beyond ...

Phase

0.43 miles

Learn More »

This long-term follow up study will enroll subjects who will be transferred from selected interventional, company sponsored trials with radium-223 dichloride (feeder trials). The primary objectives are to define the long term safety profile of radium-223 dichloride (for up to 7 years after the last dose of radium-223 dichloride); to ...

Phase

0.43 miles

Learn More »

Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF

BACKGROUND Dabigatran etexilate, a direct thrombin inhibitor and new oral anticoagulant (NOAC), has been shown to effectively prevent thromboembolic events in patients with atrial fibrillation (AF). However, there is a paucity of data on the antithrombotic efficacy and safety of dabigatran in the resolution of left atrial appendage (LAA) thrombi ...

Phase

9.33 miles

Learn More »

Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation

Oral anticoagulation treatment (OAC) following clinically successful catheter abla-tion of atrial fibrillation (AF) is controversial. Recent guidelines recommended con-tinuation of OAC in all patients with CHA2DS2VASc score 2 even if there is no evidence of recurrent AF (Camm JA et al., Eur Heart J 2012). The net clinical ben-efit of ...

Phase

9.33 miles

Learn More »

Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention

Patients with stable or clinically unstable (biomarker-negative) angina pectoris who are in need of coronary intervention will be randomly assigned in one of the treatment strategies - 60 mg of prasugrel or 600 mg clopidogrel just prior to percutaneous coronary intervention (PCI). After PCI all patients will receive clopidogrel 75 ...

Phase

9.33 miles

Learn More »